Picture loading failed.

Anti-VEGFA therapeutic antibody (Pre-made Brolucizumab biosimilar,scFv) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Brolucizumab, sold under the trade name Beovu, is a humanized single-chain antibody fragment for the treatment of neovascular (wet) age-related macular degeneration (AMD).

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-083-1mg 1mg 3090
GMP-Bios-ab-083-10mg 10mg 21890
GMP-Bios-ab-083-100mg 100mg 148000
GMP-Bios-ab-083-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-VEGFA therapeutic antibody (Pre-made Brolucizumab biosimilar,scFv)
INN Name Brolucizumab
TargetVEGFA
FormatscFv
DerivationHumanized
Species ReactivityHuman
CH1 Isotypena
VD LCKappa
Highest_Clin_Trial (Jan '20)Approved
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2014
Year Recommended2015
CompaniesESBATech;Alcon
Conditions ApprovedWet age-related macular degeneration
Conditions ActiveDiabetic macular oedema;Retinal vein occlusion;Diabetic retinopathy
Conditions Discontinuedna
Development Techna